The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial

OBJECTIVE This study compared the durability of glycemic control of twice-daily insulin lispro mix 75/25 (LM75/25: 75% insulin lispro protamine suspension/25% lispro) and once-daily insulin glargine, added to oral antihyperglycemic drugs in type 2 diabetes patients. RESEARCH DESIGN AND METHODS During the initiation phase, patients were randomized to LM75/25 or glargine. After 6 months, patients with A1C ≤7.0% advanced to the maintenance phase for ≤24 months. The primary objective was the between-group comparison of duration of maintaining the A1C goal. RESULTS Of 900 patients receiving LM75/25 and 918 patients receiving glargine who completed initiation, 473 and 419, respectively, had A1C ≤7.0% and continued into maintenance. Baseline characteristics except age were similar in this group. Median time of maintaining the A1C goal was 16.8 months for LM75/25 (95% CI 14.0–19.7) and 14.4 months for glargine (95% CI 13.4–16.8; P = 0.040). A1C goal was maintained in 202 LM75/25-treated patients (43%) and in 147 glargine-treated patients (35%; P = 0.006). No differences were observed in overall, nocturnal, or severe hypoglycemia. LM75/25 patients had higher total daily insulin dose (0.45 ± 0.21 vs. 0.37 ± 0.21 units/kg/day) and more weight gain (5.4 ± 5.8 vs. 3.7 ± 5.6 kg) from baseline. Patients taking LM75/25 and glargine with lower baseline A1C levels were more likely to maintain the A1C goal (P = 0.043 and P < 0.001, respectively). CONCLUSIONS A modestly longer durability of glycemic control was achieved with LM75/25 compared with glargine. Patients with lower baseline A1C levels were more likely to maintain the goal, supporting the concept of earlier insulin initiation.

[1]  A. Jaillard.  [The 2 diabetes]. , 1968, Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille.

[2]  Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association Declaration of Helsinki. , 1994, Le Journal medical libanais. The Lebanese medical journal.

[3]  Association World Medical,et al.  World medical association declaration of Helsinki , 2001, Chinese Journal of Integrative Medicine.

[4]  A. Fritsche,et al.  Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes , 2003, Annals of Internal Medicine.

[5]  J. Rosenstock,et al.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. , 2003, Diabetes care.

[6]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[7]  B. Campaigne,et al.  Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. , 2004, Clinical therapeutics.

[8]  Robert A Gabbay,et al.  Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. , 2005, Diabetes care.

[9]  I. Hirsch,et al.  A Real-World Approach to Insulin Therapy in Primary Care Practice , 2005 .

[10]  Workgroup on Hypoglycemia.  Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. , 2005, Diabetes care.

[11]  M. Davies,et al.  Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. , 2005, Diabetes care.

[12]  A. Farmer,et al.  Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. , 2007, The New England journal of medicine.

[13]  [Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. (A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes)]. , 2007, Problemy endokrinologii.

[14]  B. Wolffenbuttel,et al.  The DURABLE trial 24-week results , 2008 .

[15]  Honghua Jiang,et al.  The DURABLE Trial Study Design: Comparing the Safety, Efficacy, and Durability of Insulin Glargine to Insulin Lispro Mix 75/25 Added to Oral Antihyperglycemic Agents in Patients with Type 2 Diabetes , 2008, Journal of diabetes science and technology.

[16]  J. Leahy.  Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes , 2008 .

[17]  B. Wolffenbuttel,et al.  DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results , 2009, Diabetes Care.

[18]  A. Farmer,et al.  Three-year efficacy of complex insulin regimens in type 2 diabetes. , 2009, The New England journal of medicine.

[19]  H. Rodbard,et al.  Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[20]  M. Hanefeld,et al.  Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis , 2010, Diabetologia.

[21]  W. F. Miser,et al.  Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy , 2010, Clinical therapeutics.